Deadline for MM&M Awards just one day away

Share this article:
MM&M Awards 2008--and the finalists are:
MM&M Awards 2008--and the finalists are:

Don't miss the opportunity to be part of the MM&M Awards 2008. There's just one day left to submit your entries.

Submissions will be judged by an independent panel of 50 top industry leaders, thinkers and creatives.

Among this year's pharma-side judges are Jennifer Allen, Merck's director of global communications for vaccines; Deborah Dunsire, president and CEO of Millennium Pharmaceuticals; and senior marketers and communicators Ben Lei (Genentech), Kevin Nalty (Merck), Cynthia North (Bayer HealthCare), Jean-Luc Pilon (Sanofi-Aventis), Mike Pucci (GlaxoSmithKline), Jennifer Rinaldo (Forest Labs), Joe Shields (Wyeth) and Meryl Weinreb (AstraZeneca).

Agencies, too, are well represented by esteemed leaders such as Doug Burcin (Euro RSCG Life), Phil Deschamps (GSW Worldwide), Carol DiSanto (Cline Davis & Mann), Richard Nordstrom (McCann Healthcare Worldwide), Dale Taylor (AbelsonTaylor) and Sam Welch (Saatchi & Saatchi Healthcare).

Time's almost up. All you have to do is enter. Click here to download your entry kit.

Deadline for submissions is May 30, 2008. For more information on the MM&M Awards 2008, click here.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...